ライフサイエンスコーパス: cancer prevention

1 umor initiation, which is highly relevant to cancer prevention.

2 ategy, namely, reverse-engineering precision cancer prevention.

3 r guiding public health strategies of breast cancer prevention.

4 that arise, and novel strategies for ovarian cancer prevention.

5 role of dietary selenium (Se) in colorectal cancer prevention.

6 issues from various types of insults and for cancer prevention.

7 potential to save millions of lives through cancer prevention.

8 tinued structured screening program for anal cancer prevention.

9 garding all things cancer related, including cancer prevention.

10 rivate practice would have a career focus in cancer prevention.

11 crobiome in breast carcinogenesis and breast cancer prevention.

12 he public about the potentials and limits of cancer prevention.

13 mplementation of policies to improve primary cancer prevention.

14 plays a critical role in cellular stress and cancer prevention.

15 2 has been suggested to offer a strategy for cancer prevention.

16 yanins in P40 may provide extra benefits for cancer prevention.

17 re and perhaps extraordinary opportunity for cancer prevention.

18 ion with direct therapeutic implications for cancer prevention.

19 to determine the optimal use of aspirin for cancer prevention.

20 benefit-to-harm ratio of the drug for breast cancer prevention.

21 iruses (gammaHVs) is an important target for cancer prevention.

22 hallenge and an enormous opportunity in skin cancer prevention.

23 or our understanding of cancer causation and cancer prevention.

24 al and human intervention studies on tea and cancer prevention.

25 d to development of anticancer therapies and cancer prevention.

26 atase inhibitors to antiestrogens for breast cancer prevention.

27 ave transformed the practice of oncology and cancer prevention.

28 genes as potential diagnostic biomarkers for cancer prevention.

29 ation are critical for genomic stability and cancer prevention.

30 edback loop may be an important strategy for cancer prevention.

31 therapy may offer some therapeutic value in cancer prevention.

32 aped curve for micronutrients in relation to cancer prevention.

33 reening tests that offer the opportunity for cancer prevention.

34 types have the potential to improve cervical cancer prevention.

35 rly, sustained ART is a crucial component of cancer prevention.

36 odel of breast cancer, with implications for cancer prevention.

37 entially can play an important role in colon cancer prevention.

38 al to identify agents for obesity-associated cancer prevention.

39 ation is essential for genomic stability and cancer prevention.

40 a promising strategy for skin protection and cancer prevention.

41 and genomics from the perspective of global cancer prevention.

42 ming HIV-positive MSM as priorities for anal cancer prevention.

43 at unappreciated p53 functions contribute to cancer prevention.

44 ings may have important implications in skin cancer prevention.

45 Sun-protective behavior affects skin cancer prevention.

46 sed on nfGNPs for HPV detection and cervical cancer prevention.

47 g both YAP and AKT in liver size control and cancer prevention.

48 to assess the possible role of vitamin D in cancer prevention.

49 ould be an important strategy for pancreatic cancer prevention.

50 re to alcohol has important implications for cancer prevention.

51 functional foods or nutraceuticals for colon cancer prevention.

52 itamin D supplementation is useful in breast cancer prevention.

53 ly undergoing clinical evaluation as a novel cancer prevention agent.

54 clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US.

55 thus functions as an important regulator of cancer prevention and aging.

56 year, we've identified the critical gaps in cancer prevention and care that we believe to be most pr

57 Despite the huge potential importance of cancer prevention and clinical success stories such as t

58 r risk, and evaluate the potential impact of cancer prevention and control strategies on cancer rates

59 igating inflammation is clearly important in cancer prevention and control.

60 y serve as potential therapeutic targets for cancer prevention and control.

61 isk factors is crucial to inform and improve cancer prevention and control.

62 We conclude that colorectal cancer prevention and dysplasia management for patients

63 ly important questions that are critical for cancer prevention and early detection in women carrying

64 otocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.

65 ith HIV/AIDS (PLWHA) highlights the need for cancer prevention and early detection.

66 tion and progression, and will help identify cancer prevention and early intervention targets.

67 Neither breast cancer prevention and early-detection programs, nor thei

68 Objective: To characterize skin cancer prevention and education needs in uninsured, mino

69 In 2014, the Cancer Prevention and Ethics Committees of ASCO commissi

70 Cancer prevention and health promotion are also in the r

71 tive therapy is the more logical approach to cancer prevention and hypothesizes that treatment early

72 dence-informed frameworks for cost-effective cancer prevention and management are essential for deliv

73 a possible molecular basis for zinc-induced cancer prevention and Orai1-SOCE signaling pathway in ca

74 ety of health care and research settings for cancer prevention and pharmacology research.

75 ies investigating the effects of exercise in cancer prevention and progression.

76 nts: "G.B. acknowledges the support from the Cancer Prevention and Research Institute of Texas (RR140

77 Pharmacyclics Inc, Cancer Prevention and Research Institute of Texas, Leuke

78 Cancer Prevention and Research Institution of Texas and

79 Additional efforts aimed at cancer prevention and screening in people with HIV are w

80 gnize the potential of obesity management in cancer prevention and that excess body weight in women i

81 Cancer prevention and the creation of a culture of healt

82 In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and

83 es to induce clearance will be important for cancer prevention and the treatment of HPV-related disea

84 ves and analogues and their potential use in cancer prevention and therapy, which are related to thei

85 naling loop could be a new approach for lung cancer prevention and therapy.

86 SP expression may offer new targets for skin cancer prevention and therapy.

87 dation may serve as a promising strategy for cancer prevention and therapy.

88 malignant progression, with implications for cancer prevention and therapy.

89 plementation of new treatment strategies for cancer prevention and therapy.

90 agonists with minimal side effects for colon cancer prevention and therapy.

91 might therefore be an attractive option for cancer prevention and therapy.

92 eful approach for applying luteolin for lung cancer prevention and therapy.

93 which might be translationally relevant for cancer prevention and therapy.

94 ning frequency and behaviors related to skin cancer prevention and to investigate whether these assoc

95 ning frequency and behaviors related to skin cancer prevention and to investigate whether these assoc

96 diseases and suggest therapeutic targets for cancer prevention and treatment in high-risk patients.

97 ta and its biological role might lead to new cancer prevention and treatment strategies.

98 tify several promising strategies to improve cancer prevention and treatment that have emerged across

99 unravel a potential therapeutic strategy for cancer prevention and treatment through PTEN reactivatio

100 Metformin has utility in cancer prevention and treatment, though the mechanisms f

101 een metformin use and a beneficial effect on cancer prevention and treatment, which has led to increa

102 lity may be a potential agent for pancreatic cancer prevention and treatment.

103 dentified pathways may be valuable for colon cancer prevention and treatment.

104 g p38gamma may be a novel strategy for colon cancer prevention and treatment.

105 n "the race" and its consequences for breast cancer prevention and treatment.

106 tigated extensively for its effective use in cancer prevention and treatment.

107 ose that a CCR5 antagonist can serve for HCC cancer prevention and treatment.

108 ins offer exceptional promise in the area of cancer prevention and treatment.

109 F2 might be a potential molecular target for cancer prevention and treatment.

110 respiration is a promising novel avenue for cancer prevention and treatment.

111 tes to cancer etiology is important for both cancer prevention and treatment.

112 a potential target for premenopausal breast cancer prevention and treatment.

113 udies on metformin and related biguanides in cancer prevention and treatment.

114 ical suppression, a potential future mode of cancer prevention and treatment.

115 s an effective therapeutic avenue for breast cancer prevention and treatment.

116 est a role of VentX as a potential target in cancer prevention and treatment.

117 ld be valuable to the patient and family for cancer prevention and treatment.

118 CC), the inhibition of which is explored for cancer prevention and treatment.

119 omized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines f

120 rtance of sun protection and facilitate skin cancer prevention and, therefore, decrease the skin canc

121 interest in possible roles of biguanides in cancer prevention and/or treatment.

122 the most investigated selenium compounds in cancer-prevention and -therapy.

123 ealth benefits, including anti-inflammation, cancer prevention, and anti-diabetes.

124 ffects of anti-oestrogen treatment in breast cancer prevention, and suggest that fibroblast growth fa

125 n to cancer risk, discusses implications for cancer prevention, and suggests future research directio

126 s, reports on FGFR inhibitor-mediated breast cancer prevention are sparse.

127 indicated they would likely be interested in cancer prevention as a career focus, although only 12% t

128 of men: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study and the Prostate, Lung, C

129 the Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

130 ments in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

131 serum in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

132 Among patient factors related to cancer prevention behaviors, patients' stated behavioral

133 netically engineered mouse models but weaker cancer prevention benefit in chemically induced rat mode

134 s may represent a modifiable risk factor for cancer prevention (breast in particular), contributing t

135 avirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectivenes

136 ty would have been an effective strategy for cancer prevention, but the reality is that worldwide obe

137 health information, including advice on skin cancer prevention, but their effectiveness may be affect

138 ajor role in regulating genome stability and cancer prevention by controlling the key proteins involv

139 ns unclear whether MSA exerts its effects on cancer prevention by influencing angiogenesis within Se

140 se findings suggest opportunities for breast cancer prevention by modifying individual estrogen metab

141 a driver for p53 mutagenesis and a guide for cancer prevention by NSAID treatment.

142 3 mutations in specific types of tumors, and cancer prevention by regular usage of NSAIDs.

143 co Cessation and Control Subcommittee of the Cancer Prevention Committee (CaPC).

144 The Cancer Prevention Committee of the American Society of C

145 al trials of supplemental micronutrients for cancer prevention completed over the past 20 years, incl

146 Colon cancer prevention currently relies on colonoscopy using

147 ion, this calling for a continuous effort in cancer prevention, early diagnosis, and treatment.

148 burden of cancer, societal attitudes towards cancer prevention, effects of inequitable treatment and

149 ctal cancer, at least in men, and colorectal cancer prevention efforts should encourage the achieveme

150 efore, beta HPV represents a target for skin cancer prevention, especially in high-risk populations.

151 Most addressed issues of cancer prevention, followed by diagnosis, survivorship,

152 is a necessary step in order to move stomach cancer prevention forward to population-based precision

153 search for dietary factors on which to base cancer prevention guidelines has led to the rapid expans

154 herence to the American Cancer Society (ACS) cancer prevention guidelines is associated with a reduct

155 Conventional cancer prevention has primarily focused on single chemop

156 ons, the mechanisms linking COX blockade and cancer prevention have long been an area of active inves

157 ials that have led to licensure for cervical cancer prevention have used the disease endpoint of cerv

158 abstracted from the American Cancer Society Cancer Prevention II Study cohort, with baseline ascerta

159 collaborative approaches, enhancing cervical cancer prevention, improving cancer surveillance and pal

160 bservation that NSAIDs are most effective in cancer prevention in APC(min/+) mice if the mice are tre

161 For targeted secondary anal cancer prevention in high-risk groups, HIV-negative wome

162 istance to cancer may lead to new methods of cancer prevention in humans.

163 el, supporting its further consideration for cancer prevention in LFS patients.

164 formin, a first-line diabetes drug linked to cancer prevention in retrospective clinical analyses, in

165 ld therefore be a strong candidate for liver cancer prevention in the context of aberrant Smad3 signa

166 the substantial importance of DNA repair in cancer prevention in the general population.

167 upplements are not currently recommended for cancer prevention in the general population.

168 t is important to identify obstacles in skin cancer prevention in these communities.

169 ovide a unique prophylactic therapy for skin cancer prevention in XP-C patients.

170 of potential scale-up scenarios for cervical cancer prevention, in order to predict the future incide

171 tobacco smoke-constituent biomarkers in lung cancer prevention, including improved lung cancer risk a

172 d from 51 hospitals into the Ohio Colorectal Cancer Prevention Initiative from January 1, 2013, to Ju

173 ing basic, translational, epidemiologic, and cancer prevention initiatives.

174 ogenesis mechanisms and provided a basis for cancer prevention initiatives.

175 d Hispanics are particularly in need of skin cancer prevention interventions.

176 Reluctance to incorporate cancer prevention into an oncology career seems to stem

177 Therapeutic cancer prevention is a developing area that can gain a l

178 Effective cancer prevention is based on accurate molecular diagnos

179 vidence comparing ICR to CCR with respect to cancer prevention is controversial and inconclusive.

180 The role of vitamin D in breast cancer prevention is equivocal.

181 munity-based H. pylori screening and stomach cancer prevention is feasible and acceptable.

182 Low-dose aspirin for cancer prevention is often cited as the most important a

183 Cancer prevention is predicted to result in more positiv

184 However, aspirin's role in cancer prevention is still emerging, and no groups curre

185 The major goal of breast cancer prevention is to reduce the incidence of ductal c

186 Following the lifestyle guidelines for cancer prevention may improve HRQOL among elderly female

187 herence to the WCRF/AICR recommendations for cancer prevention may lower the risk of developing most

188 These findings could be used to target lung-cancer prevention measures to high-risk groups.

189 tion to tamoxifen and raloxifene as a breast cancer prevention medication, although exemestane is not

190 t cancer of 1.66% or greater, discuss breast cancer prevention medications with their primary care pr

191 d provide incentive for reducing weight as a cancer prevention method in overweight and obese individ

192 pants were recruited through the multicenter Cancer Prevention Network and randomly assigned to group

193 Cancer prevention occurs by arresting, slowing down, or

194 physical activity, and weight management for cancer prevention on the basis of the most comprehensive

195 physical activity, and weight management for cancer prevention on the basis of the most comprehensive

196 atase inhibitors to antiestrogens for breast cancer prevention.Oncogene advance online publication, 2

197 intestine, thus playing an essential role in cancer prevention or cancer promotion.

198 lation of promoter CpG islands may offer new cancer prevention or therapeutic approaches.

199 city, it could be potentially used for colon cancer prevention or therapy.

200 sent a novel therapeutic approach for breast cancer prevention or treatment based on its pharmacologi

201 dulation of selective sirtuin members to aid cancer prevention or treatment under defined conditions.

202 ons in developing a new metabolic diagram of cancer prevention or treatment.

203 bitors of GPER1 might be developed for liver cancer prevention or treatment.

204 could be an attractive strategy for prostate cancer prevention or treatment.

205 an effective therapeutic target for ovarian cancer prevention or treatment.

206 have been conducted in the field of prostate cancer prevention over the past decade.

207 cal Adjuvant Breast and Bowel Project Breast Cancer Prevention P-1), MA.17, and BIG 1-98 (Breast Inte

208 ic evaluation at a time when global cervical cancer prevention policy continues to evolve and evidenc

209 f breast cancer risk that may improve breast cancer prevention programs.

210 tudy uncover a potential target for cervical cancer prevention, provide insight into the risk assessm

211 tudy was to examine whether adherence to the cancer prevention recommendations of the World Cancer Re

212 nes encourage cancer survivors to follow its cancer prevention recommendations.

213 Skin cancer prevention remains a national priority.

214 Cancer Prevention Research Institute of Texas, Red and C

215 Thus, identifying an important area for cancer prevention research.

216 Cancer Prevention & Research Institute of Texas and Cent

217 These results are important for strategizing cancer prevention, research and public health.

218 that are central to the state-of-the-art of cancer prevention science.

219 with the potential to accelerate advances in cancer prevention, screening, and early detection across

220 recommendation for green tea consumption for cancer prevention should be made.

221 er in cancer heterogeneity and suggests that cancer prevention should target precancerous cells broad

222 ies, such as anti-oestrogen drugs for breast cancer prevention, should be targeted to high-risk group

223 explore known and potential various types of cancer prevention strategies and focus on nonvaccine-bas

224 dominally obese individuals may be important cancer prevention strategies as well as adjuvant therapi

225 Regional adoption of effective primary cancer prevention strategies has a vast potential to red

226 These findings suggest that breast cancer prevention strategies with HDAC/DNMT inhibitors n

227 pulations may facilitate targeted colorectal cancer prevention strategies.

228 comprising this index may inform population cancer prevention strategies.

229 avenue to explore further in the search for cancer-prevention strategies.

230 Such cancer prevention strategy may be critical for high-risk

231 esults render FASN as a potential target for cancer prevention studies.

232 ancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (n = 29,104 men), conducted in 1

233 ancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (n=29,104 men) conducted between

234 s within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.

235 y mortality from the American Cancer Society Cancer Prevention Study II (ACS CPS-II) cohort have been

236 residence of 668,629 American Cancer Society Cancer Prevention Study II (CPS-II) cohort participants

237 te cancer mortality among 363,726 men in the Cancer Prevention Study II (CPS-II) cohort, of whom 7,45

238 249 postmenopausal, cancer-free women in the Cancer Prevention Study II (CPS-II) Nutrition Cohort, en

239 centrations and lung cancer mortality in the Cancer Prevention Study II (CPS-II), a large prospective

240 r pollution with nonlung cancer death in the Cancer Prevention Study II (CPS-II).

241 articipants from the American Cancer Society Cancer Prevention Study II cohort were linked to modeled

242 bestos-exposed blue collar male workers from Cancer Prevention Study II for whom occupational and smo

243 were aged 30-89 years at their enrollment in Cancer Prevention Study II in 1982.

244 Adults enrolled in Cancer Prevention Study II in 1982/1983 were followed fo

245 ort studies: (1) the American Cancer Society Cancer Prevention Study II Nutrition Cohort and (2) the

246 The Cancer Prevention Study II Nutrition Cohort collected in

247 Men in the Cancer Prevention Study II Nutrition Cohort diagnosed wi

248 cipants (60,059 men and 73,196 women) in the Cancer Prevention Study II Nutrition Cohort during the p

249 ned among 55,983 men and 66,655 women in the Cancer Prevention Study II Nutrition Cohort from 1992 to

250 62,792 men and 69,520 women enrolled in the Cancer Prevention Study II Nutrition Cohort in 1992, we

251 ta-Carotene Cancer Prevention Study, and the Cancer Prevention Study II Nutrition Cohort to investiga

252 ake with risk of NHL and NHL subtypes in the Cancer Prevention Study II Nutrition Cohort, a prospecti

253 es of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Health

254 n Retired Persons Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Multiet

255 A total of 132,823 participants in the Cancer Prevention Study II Nutrition Cohort, who were fo

256 estigated their associations with CRC in the Cancer Prevention Study II Nutrition Cohort.

257 Cancer Prevention Study II participants were enrolled in

258 ditive scale between these risk factors from Cancer Prevention Study II, a large prospective US cohor

259 ake with fatal oral/pharyngeal cancer in the Cancer Prevention Study II, a prospective US cohort stud

260 trols in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish men.

261 g Trial, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, and the Cancer Prevention Study

262 and women from 23 states who enrolled in the Cancer Prevention Study-3 cohort during 2006-2009 and ha

263 (random sub-cohort N=1,685) from the Korean Cancer Prevention Study-II (KCPS-II) (N=145,842) was use

264 established in the American Cancer Society's Cancer Prevention Study-II cohort.

265 7 adults aged 30-89 years at enrollment into Cancer Prevention Study-II in 1982.

266 Cancer Prevention Study-II Nutrition Cohort participants

267 r rectal cancer between 1992 and 2007 in the Cancer Prevention Study-II Nutrition Cohort, a prospecti

268 sal women with serum metabolomic data in the Cancer Prevention Study-II Nutrition Cohort, we conducte

269 women and men in the American Cancer Society Cancer Prevention Study-II Nutrition Cohort.

270 Among 138,003 Cancer Prevention Study-II participants, 2,532 incident

271 ATBC Study (Alpha-Tocopherol, Beta-Carotene Cancer Prevention) that originally tested vitamin E and

272 ce that prebiotics play a role in colorectal cancer prevention, their role of satiety and weight mana

273 regulation of the pathway might be useful in cancer prevention, treatment, and regenerative medicine

274 baseline in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003).

275 o participated in the Selenium and Vitamin E Cancer Prevention Trial (2001-2011) with present analyse

276 Using data from the Prostate Cancer Prevention Trial (n = 5,986), we evaluated prosta

277 In the Prostate Cancer Prevention Trial (PCPT), finasteride significantl

278 tive randomized trials, such as the Prostate Cancer Prevention Trial (PCPT), Reduction by Dutasteride

279 The Selenium and Vitamin E Cancer Prevention Trial (SELECT) Eye Endpoints Study was

280 from the large-scale Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed that antioxidant

281 te cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) through unknown mechani

282 was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical

283 s (REDUCE) trial, and Selenium and Vitamin E Cancer Prevention Trial (SELECT), have provided practiti

284 prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin

285 tion Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to defin

286 R (Study of Tamoxifen and Raloxifene) breast cancer prevention trial and in other clinical trials.

287 Another large, Phase III prostate cancer prevention trial showed no benefit for either sel

288 carriers leading to an international breast cancer prevention trial, and insights into the intricate

289 thin the Mammary Prevention.3 (MAP.3) breast cancer prevention trial.

290 d, double-blind, placebo-controlled, primary cancer prevention trial; participants were Finnish male

291 from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Tri

292 large, population-based, Phase III prostate cancer prevention trials have shown a significant benefi

293 nly used to determine eligibility for breast cancer prevention trials was greatly increased relative

294 sion Among screened men enrolled in prostate cancer prevention trials, differences in risk factor est

295 ys essential roles in organ size control and cancer prevention via restricting its downstream effecto

296 Screening detection, rather than long-term cancer prevention, was evaluated.

297 Considering these roles and cancer prevention, we hypothesized that tumor CTNNB1 sta

298 ns and Relevance: Important barriers to skin cancer prevention were lack of knowledge, the belief tha

299 plant-based foods seem promising for stomach cancer prevention, while vitamin C lowers the risk of es

300 t to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeut